Tianda Pharmaceutical (00455) announced interim results. Shareholders' share loss of HK$32.25 million narrowed by 2.97% year-on-year

According to the Zhitong Finance App, Tianda Pharmaceutical (00455) announced its 2026 interim results, with revenue of about HK$164 million, up 20.19% year on year; loss attributable to the company's shareholders was HK$32.25 million, a decrease of 2.97% year on year; loss per share was HK$1.5 million.

The announcement stated that during the period, the Group continued to optimize sales strategies, integrate resources and improve operational efficiency, consolidate the core product market base, expand diversified channels, promote innovative research and development of traditional Chinese medicine and product pipeline construction, and improve the layout of the entire traditional Chinese medicine industry chain. The Group has strengthened refined management, reduced costs and increased efficiency, achieved double-digit growth in overall revenue, and improved business quality.